%0 Journal Article
%T The clinical utility of gene testing for Alzheimer¡¯s disease
%A Emily R. Atkins
%A Peter K. Panegyres
%J Neurology International
%D 2011
%I PAGEPress Publications
%R 10.4081/ni.2011.e1
%X Alzheimer¡¯s disease (AD) is the largest cause of dementia, affecting 35.6 million people in 2010. Amyloid precursor protein, presenilin 1 and presenilin 2 mutations are known to cause familial early-onset AD, whereas apolipoprotein E (APOE) ¦Å4 is a susceptibility gene for late-onset AD. The genes for phosphatidylinositol- binding clathrin assembly protein, clusterin and complement receptor 1 have recently been described by genome-wide association studies as potential risk factors for lateonset AD. Also, a genome association study using single neucleotide polymorphisms has identified an association of neuronal sortilin related receptor and late-onset AD. Gene testing, and also predictive gene testing, may be of benefit in suspected familial early-onset AD however it adds little to the diagnosis of lateonset AD and does not alter the treatment. We do not recommend APOE ¦Å4 genotyping.
%K Neurology
%K Alzheimer's disease
%K gene testing
%U http://www.pagepress.org/journals/index.php/ni/article/view/2140